bluuebunny/crossref_metadata_2025_split huggingface dataset:
837-P: Closed-Loop Insulin Delivery Improves Glycemic Control In Paediatric Patients with Type 1 Diabetes—A Systematic Review
Authors: CHANDANAA KISTIPATI HARI , VISHNUBHAI ZEEL P. , ASHRAF SAAD , GHOSH SHANKHANEEL , TUMMALA NAYANIKA , ROY POULAMI , DEB NOVONIL , MADDINENI GAUTAM 
Published: June 2024

Background: Type 1 Diabetes (T1D) in pediatric patients presents significant challenges in achieving optimal glycemic control. Closed-loop insulin delivery systems offer a modern approach to managing blood glucose levels by using continuous glucose monitoring data to adjust insulin delivery. This review aims to evaluate the impact of closed-loop insulin delivery on glycemic control in pediatric patients with T1D.
Methods: We searched PubMed, Scopus, Embase, and the WoS from their inception until June 2023 to identify relevant studies. We included studies focusing on closed-loop insulin delivery systems in children aged 0 to 18 with T1D. Our primary goal was to measure improved glycemic control by analyzing HbA1c changes.We extracted data and used established tools to assess the quality of the studies.
Results: 15 studies met the inclusion criteria, encompassing various closed-loop systems, including Continuous Subcutaneous Insulin Infusion (CSII), Dexcom G4, Florence D2, Omnipod 5, Medtronic Minimed, Minilink®REAL, Animas, and CamAPS FX. The studies demonstrated heterogeneous findings in glycemic control improvement, with significant reductions in HbA1c levels observed in most systems. Some variations were noted in outcomes, attributed to differences in study populations, system types, and study durations. A few studies reported adverse events such as diabetic ketoacidosis and sensor issues.
Conclusion: Closed-loop insulin delivery systems promise to enhance glycemic control in pediatric patients with T1D. While many studies reported favorable outcomes, further research is needed to understand system-specific effects, ensure safety, and address young patients' unique challenges. Standardizing outcome measures and conducting cost-effectiveness analyses are critical for broader adoption and successful integration into clinical practice.

Disclosure
H. Kistipati: None. Z.P. Vishnubhai: None. S. Ashraf: None. S. Ghosh: None. N. Tummala: None. P. Roy: None. N. Deb: None. G. Maddineni: None.
9-OR: ADA Presidents' Select Abstract: Targeting Inflammation with Salsalate in Type 1 Diabetes Neuropathy (TINSAL-T1DN Trial)
Authors: ANG LYNN , HUANG YIYUAN , MARTIN CATHERINE , MIZOKAMI-STOUT KARA R. , KUEI LIN YU , VASBINDER ALEXI , BANERJEE MOUSUMI , HAYEK SALIM , FELDMAN EVA L. , BUSUI RODICA 
Published: June 2024

Introduction & Objective: Diabetic peripheral neuropathy (DPN) and cardiovascular autonomic neuropathy (CAN) are highly prevalent complications of diabetes without effective disease-modifying treatments. Chronic inflammation and the NFkB pathway have emerged as important mechanisms. We aimed to assess the effectiveness and safety of salsalate, a NFkB blocker, in individuals with type 1 diabetes (T1D) and DPN.
Methods: This was a phase 2/3, randomized, double-blind clinical trial of salsalate 3 grams daily vs placebo for 12 months. The primary outcome was the change in intraepidermal nerve fiber density (IENFD) at the distal thigh at 12 months. Secondary outcomes included IENFD at distal leg, nerve conduction studies and measures of CAN (standardized cardiovascular autonomic reflex tests, heart rate variability). Linear regressions were used to assess percent changes in all outcomes between groups.
Results: Fifty-five participants with T1D (mean age 51±12 years, baseline HbA1c 8.4±1.7%, duration 29±14 years) and mild to moderate DPN completed the trial. No significant differences were found in the primary outcome after 12 months. However, positive trends were noted in several secondary outcomes (salsalate vs placebo): sural amplitude (15% vs -10%; p=0.058), sural nerve conduction velocity (9% vs -4%; p=0.16), and measures of CAN (root mean square of the differences of successive RR intervals 34% vs 7%, expiration/inspiration ratio 6% vs -1%, and the 30:15 ratio 19% vs -5%) (p &gt;0.05 for all). After adjusting for age, gender, diabetes duration, HbA1c, BMI, baseline IENFD at distal leg and thigh, sural amplitude significantly improved (31%; p= 0.031) with salsalate.
Conclusion: In this small T1D cohort, salsalate treatment did not significantly change IENFD at distal thigh at 12 months. Trends toward improvement in the sural amplitude and other outcomes suggest salsalate’s potential as a disease-modifying therapy in T1D neuropathy, necessitating larger trials.

Disclosure
L. Ang: None. Y. Huang: None. C. Martin: None. K.R. Mizokami-Stout: None. Y. Lin: None. A. Vasbinder: None. M. Banerjee: None. S. Hayek: None. E.L. Feldman: None. R. Busui: Board Member; American Diabetes Association. Consultant; Procter & Gamble, AstraZeneca, Averitas Pharma, Inc., Bayer Inc., Lexicon Pharmaceuticals, Inc., Nevro Corp., Ono Pharmaceutical Co., Ltd., Novo Nordisk, Roche Diagnostics. Advisory Panel; ADA/ACC Diabetes by Heart Program.

Funding
NIH/NIDDK-1-R01-DK-107956-01
926-P: Early Sodium–Glucose Cotransporter 2 Inhibitors–Induced Change in Haematocrit as a Predictor of Mortality and Cardiovascular Risk—A Real-World Study
Authors: TOULIS KONSTANTINOS A. , WANG JINGYA , TAN LUYUAN , NIRANTHARAKUMAR KRISHNARAJAH , NAUCK MICHAEL A. 
Published: June 2024

Introduction & Objective: Statistical and mechanistic evidence suggest that sodium-glucose co-transporter 2 inhibitors (SGLT2i)-induced change in haematocrit may affect cardiovascular risk. Since the magnitude of change is variable but manifested early, we explored whether the within 6-month changes in haematocrit in subjects initiated with SGLT2i could help identify those who would benefit most in terms of cardiovascular risk reduction.
Methods: Using real-world data in GPRD GOLD and Aurum, a series of open cohort studies were performed in individuals with diabetes mellitus type 2 (T2DM). Primary outcome was composite end-point including all-cause mortality, myocardial infarction ischaemic heart disease and stroke. Based on linearity analyses and clinical interpretability, individuals were categorised into three subgroups of the observed absolute haematocrit change (“negative”, “positive” = 0-4, “highly positive”=&gt;4). Primary analysis was conducted with competing cox proportional hazard model with restricted cubic spline.
Results: A total of 37,2336 individuals, over 40 years-old, with T2DM under treatment with SGLT2i were included and followed for ~2.4 years with a total observation worth of ~86000 person-years. The subgroup with the negative haematocrit change was found to be at a significantly increased risk of manifesting the composite outcome [adjusted hazard ratio and 95% confidence intervals, aHR (95% CI): 1.23 (1.12, 1.36)], death from any cause [1.33 (1.19,1.49]) and heart failure [1.35 (1.14, 1.60)], compared to the reference group. 0-9.83%). Sensitivity analyses did not alter the findings.
Conclusion: Among individuals with T2DM at low baseline risk of cardiovascular disease, an early increase in haematocrit after SGLT2i institution may be regarded as an indicator of future cardiovascular benefit.

Disclosure
K.A. Toulis: None. J. Wang: None. L. Tan: None. K. Nirantharakumar: Consultant; Boehringer-Ingelheim. Research Support; GlaxoSmithKline plc. M.A. Nauck: Advisory Panel; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Merck & Co., Inc. Speaker's Bureau; Merck & Co., Inc. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk, Medscape. Advisory Panel; Pfizer Inc., Structure Therapeutics, Inc., Sun Pharmaceutical Industries Ltd. Speaker's Bureau; Medical Learning Institute, Medfyle. Advisory Panel; Regor. Other Relationship; Inventiva Pharma.

Funding
EFSD Future Leaders Mentorship Programme for Clinical Diabetologists (supported by an unrestricted educational grant from AstraZeneca)
95-OR: Diurnal Variation of Islet Autoantibodies in Established Type 1 Diabetes
Authors: DIMEGLIO LINDA A. , BEAM CRAIG , PEARSON JAMES A. 
Published: June 2024

Introduction: Accurate pancreatic islet autoantibody (Aab) measurement is vital for risk-screening, early-stage treatment, and prevention study eligibility assessment in persons with and at risk of type 1 diabetes (T1D). Although Aab measurement has been standardized by addressing lab assay differences, intra-individual variation in these assays by time of day has not yet been carefully assessed.
Objective: To assess the extent of Aab diurnal variation in persons with established T1D.
Methods: Ten persons (mean age 27y) within 1-19y post T1D diagnosis had 6 blood samples taken at 4-h intervals starting at 09:00. Aab titers were measured by radiobinding assays and diurnal patterns investigated using a “Cosinor” method.
Results: We observed daily within-subject differences in Insulin Aab (IAA) titers (max-min) with a median daily difference of 18 units and variation as great as 80 units in one individual. Aab titer differences affected assay sensitivity; one person was IA-2 Aab positive on samples taken at 09:00, 13:00 and 21:00, yet negative at the other 3 times. IAA levels followed a 24-h single phase cosine curve (p=0.0028) with peak IAA titer estimated at 04:08 hrs (95% confidence interval: 01:34 to 06:34). Zinc Transporter 8 Aabs also varied according to this pattern (ZnT8RA p=0.0057 and ZnT8WA p&lt;0.0001) with morning peaks: ZnT8RA peak at 07:06 (04:07, 09:55), ZnT8WA at 08:55 (05:41, 12:10). Variance components analyses implied that sample time of day was a greater source of variation than intra-assay variation alone for IAA, GADA and ZnT8WA.
Conclusion: Circulating islet Aab titers vary significantly over 24 hrs, and Aab detection can be time-of-day dependent. Since our pilot data suggest several Aab peak in the morning, morning may be the best time of day for Aab detection. Our findings only reflect variations occurring in established T1D and therefore should be investigated in other T1D populations. Diurnal variation as a source of Aab variation must be considered in future efforts to improve Aab measurements.

Disclosure
L.A. DiMeglio: Research Support; Dompé, Lilly Diabetes, MannKind Corporation, Medtronic, Provention Bio, Inc., Sanofi, Zealand Pharma A/S, Amgen Inc. Advisory Panel; Vertex Pharmaceuticals Incorporated, Abata Therapeutics. C. Beam: None. J.A. Pearson: None.

Funding
JDRF INO-2017-458-A-N Indiana NIH UL1TR001108
972-P: Hyperglycemia from Real-World Dawn Phenomenon Is Nearly Eliminated with the MiniMed 780G System (MM780G)
Authors: MCVEAN JENNIFER , SHIN JOHN , NIU FANG , DIAZ-GARELLI FRANCK , VIGERSKY ROBERT A. 
Published: June 2024

Introduction: Many people with T1D experience an early-morning rise in glucose (i.e., dawn phenomenon, DP). The MM670G/770G with 5-min auto basal insulin reduced the burden of managing DP.1 With MM780G frequent (every 5-min) autocorrections, we hypothesized that DP hyperglycemia would be reduced further. In this analysis, the impact of the MM780G against real-world DP in adolescents and adults with T1D was evaluated.
Methods: Prevalence of DP was defined as an elevation (&gt;20mg/dL) in sensor glucose (SG) from 3AM to 6AM, compared to 12AM to 3AM, at least 30% of nights. DP was assessed among MM780G users (aged ≥16 years) in the U.S. who consented to share data. DP and glycemic outcomes (mean glucose, time in ranges and insulin delivery) were assessed in 6026 overall users and 1303 who used recommended settings (RS, a glucose target of 100mg/dL with active insulin time of 2 hours for 95% of the time).
Results: Transition from the MM770G to the MM780G decreased DP rates from 12.2% to 4.5% in all users, and to 3.0% in RS users. Glycemic outcomes were significantly improved with the MM780G (Table), consistent with the trend observed in DP rates. The % of total insulin delivered as auto bolus from 3AM to 6AM was 10.6% and 11.3% for use of all settings and RS, respectively.
Conclusion: Hyperglycemia from real-world DP was nearly eliminated by the MM780G system due to the ability of its algorithm to autocorrect frequently overnight.

Disclosure
J. McVean: Employee; Medtronic. J. Shin: None. F. Niu: None. F. Diaz-Garelli: Employee; Medtronic. R.A. Vigersky: Employee; Medtronic.
982-P: The Dexcom Community Glucose Monitoring Project for People with Type 2 Diabetes—One-Year Outcomes
Authors: GRACE THOMAS , LAYNE JENNIFER E. , HICKS CHRISTIAN , GREEN COURTNEY R. , WALKER TOMAS C. 
Published: June 2024

Background & Objective: Access to CGM for people with type 2 diabetes (T2D) remains limited, especially for those treated in the primary care setting. The objective of this study, a collaboration between a primary care practice and the local public health department, was to evaluate the glycemic impact of CGM access on adults with T2D.
Methods: CGM systems (Dexcom G6 and G7) were provided to eligible participants with T2D who were ≥18 years of age, CGM-naïve, and did not have health insurance coverage for CGM. Outcomes included changes in A1C and CGM metrics from baseline to one year.
Results: Participants (n=177) were (mean ± SD) 59.1 ± 12.0 years, 41.2% female, BMI 35.5 ± 8.5, duration of diabetes 11.1 ± 9.3 years. After one year, A1C decreased from 9.4% ± 1.6 to 7.1% ± 1.3 (-2.3% ± 1.9, p&lt;0.001). The proportion of participants meeting the ADA target of A1C &lt;7.0% increased from n=1 (0.6%) at baseline to n=91 (51.4%) at one year. Those meeting the HEDIS target of A1C &lt;8.0% increased from 19.2% at baseline to 85.9% at one year. CGM outcomes (n=109) after near-continuous use included an increase in TIR of 9.9% ± 29.4 (p&lt;0.001) and a large increase in TITR (p&lt;0.001, Table).
Conclusion: Self-guided use of CGM by primary care patients with T2D for one year was associated with clinically meaningful improvements in A1C and TIR.

Disclosure
T. Grace: Speaker's Bureau; Sanofi, Novo Nordisk, Eli Lilly and Company, Dexcom, Inc. Employee; Dexcom, Inc. J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. C. Hicks: Employee; Dexcom, Inc. C.R. Green: Employee; Dexcom, Inc. T.C. Walker: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc.
999-P: Trends and Characteristics of Continuous Glucose Monitoring Initiation in Older Adults with Diabetes—A Cohort Study
Authors: ALKABBANI WAJD , PAIK JULIE M. , KIM DAE H. , MUNSHI MEDHA , WEXLER DEBORAH J. , PATORNO ELISABETTA 
Published: June 2024

Introduction & Objective: The use of continuous glucose monitoring (CGM) devices improves glycemic outcomes and minimizes hypoglycemia in older adults with diabetes. Herein, we assessed the temporal trends and characteristics of CGM initiation in this population.
Methods: Using Medicare fee-for-service data (2013-19), we identified two cohorts of patients aged ≥65 years with type 2 and type 1 diabetes and estimated the annual proportion of CGM initiation. In each cohort, we 1:4 matched new users of CGM to patients unexposed to CGM, using risk set sampling. Index date was the date of CGM initiation or, for controls, the closest physician visit within +/-7 days. We used logistic regression to assess patient characteristics associated with CGM initiation.
Results: The annual proportion of CGM initiators increased from 7 to 33/100,000 patients with type 2 diabetes and from 111 to 393/100,000 patients with type 1 diabetes. Low frailty and white race were associated with higher odds of CGM initiation in both cohorts. CGM initiators with type 2 diabetes were more likely to have history of hypoglycemia, and to be on insulin, glucagon-like peptide 1 receptor agonists, or sulfonylureas.
Conclusion: CGM initiation has significantly increased over time among older adults with type 2 and type 1 diabetes; however racial and ethnic disparities were observed.

Disclosure
W. Alkabbani: None. J.M. Paik: None. D.H. Kim: None. M. Munshi: Consultant; Sanofi. D.J. Wexler: Other Relationship; Novo Nordisk. E. Patorno: Research Support; Boehringer-Ingelheim, Food and Drug Administration (FDA), National Institutes of Health, Patient-Centered Outcomes Research Institute.
Pemanfaatan Cairan Asam Laktat dari Fermentasi Limbah Kubis (Brassica Oleracea) untuk Pengawetan Buah Tomat dan Anggur
Authors: Maulinasari Dhita , Sugiharto Agung , Khuzaimah Siti , Estiyantara Nurhadi 
Published: June 2024

Larutan limbah kubis (Brassica oleracea) merupakan hasil akhir dari fermentasi limbah kubis. Solusi ini dapat digunakan sebagai pengawet alami untuk buah-buahan. Limbah kubis menghasilkan asam laktat. Asam laktat bersifat asam dan digunakan untuk menurunkan pH dan menekan pertumbuhan bakteri lain, termasuk yang mudah rusak. Asam laktat ini dapat dibentuk melalui proses fermentasi yang berlangsung dengan adanya aktivitas spontan Lactobacillus. Tujuan dari penelitian ini adalah untuk mengetahui efektifitas limbah kubis (Brassica Oleracea) dalam mengawetkan buah anggur dan tomat melalui uji organoleptik. Penggunaan larutan limbah kubis (Brassica Oleracea) sebagai pengawet alami yang sederhana dan efektif, serta memberikan fakta kepada masyarakat tentang limbah kubis yang dapat digunakan sebagai pengawet alami yang tidak berbahaya. Penelitian ini dilakukan dengan enam perlakuan yaitu buah anggur dan tomat tanpa perendaman (kontrol), buah anggur dan tomat direndam selama 1 hari, 2 hari hingga 5 hari. Variasi perendaman buah anggur dan tomat ini berpengaruh nyata terhadap rasa, warna, aroma, dan tekstur yang dibuktikan dengan melakukan uji organoleptik. Berdasarkan hasil uji organoleptik, untuk buah anggur tanpa perendaman mengalami penyusutan yang cukup signifikan di hari ke-5 yaitu dengan berat 4,623 gr, sedangkan untuk buah anggur dengan perendaman mengalami penyusutan pada hari ke-6 dengan berat 1.675 gr. Untuk buah tomat tanpa perendaman, mengalami penyusutan yang cukup signifikan di hari ke-5 yaitu dengan berat 4.239 gr, sedangkan untuk buah tomat dengan perendaman mengalami penyusutan pada hari ke-6 dengan berat 0.881 gr
Participatory Budgeting as a Democratic and Managerial Innovation: Recent Trends and Avenues for Further Research5
Authors: Klimovský Daniel , Secinaro Silvana , Baláž Martina Benzoni , Brescia Valerio 
Published: June 2024

Abstract
Participatory budgeting was introduced in Latin America in 1989, and within 10 years, this innovation spread all over the world. At the same time, researchers outside Latin America showed a growing interest in the issue, resulting in more diversified research. A few scholars have already tried to provide comprehensive literature reviews; however, these efforts have had a narrow focus or have appeared as embedded parts of analyses of specific issues. This article aims to (1) identify recent worldwide research trends in participatory budgeting, (2) identify the most popular issues addressed by international research and (3) suggest avenues and subfields of further research. We employed bibliometric techniques to analyse articles published in journals that were indexed and abstracted in the Web of Science database from 2001 to 2020.
Life and Survival Table of Trichogramma Atopovirilia Oatman & Platner (Hymenoptera: Trichogrammatidae) in Eggs of Anticarsia Gemmatalis Hübner (Lepidoptera: Noctuidae), Subjected to Three Food Sources
Authors: Piffer Ana Beatriz Mamedes , Oliveira Ana Carolina Lopes Francisco de , Pratissoli Dirceu , Oliveira Regiane Cristina de , Vianna Ulysses Rodrigues , Pancieri Guilherme Pratissoli 
Published: June 2024

Objective: Aiming to evaluate the impact of pest management practices and different cultivation systems, the objective of this work was to evaluate the quality of Anticarsia gemmatalis eggs, fed with resistant or susceptible soybean leaves, on the Trichogramma atopovirilia fertility life table.

Method: A. gemmatalis eggs from resistant and susceptible soybean leaves were offered daily for parasitism by T. atopovirilia, in addition to an artificial diet until the death of the parasitoids. The average time of a generation (T), the net reproduction rate (Ro), the intrinsic rate of population growth (rm), the finite rate of population growth (λ) and the time required for the parasitoid population were evaluated. double the number of individuals (DT).

Results and Discussion: The life table was not affected by the food substrates used. The reproduction and development of T. atopovirilia in A. gemmatalis indicates

Research Implications: In soybean cultivation, one of the main methods of managing insect pests is synthetic chemical insecticides. A sustainable management alternative is the use of natural enemies of pests. However, to compose integrated management programs it is important to know the behavior of the pest and the natural enemy, verifying their potential.

Originality/Value: This research contributes to the knowledge of the behavior of the predator T. atopovirilia on A. gemmatalis in soybean crops with resistant varieties, indicating the possible use of this organism to form part of the integrated pest management program in the aforementioned crop, promoting more sustainable agriculture.
Profil Penyesuaian Diri Pada Peserta Didik Kelas X SMA Negeri 8 Semarang
Authors: Tri Susilo Hesti Ningrum  
Published: June 2024

Penelitian Profil Penyesuaian Diri pada Peserta Didik Kelas X SMA Negeri 8 Semarang ini dilatar belakangi masih terdapat siswa belum bisa menyesuaikan diri di lingkungan sekolah. Berdasarkan Analisis Kebutuhan Peserta Didik (AKPD) kelas X menunjukkan bahwa masih terdapat siswa yang belum mampu menyesuaikan diri dengan lingkungan sekolah baik itu menyesuaikan dengan pelajaran di sekolah, guru, maupun kesulitan dalam bergaul dengan teman sebayanya. Tujuan dari penelitian ini yakni untuk memahami profil penyesuaian diri pada peserta didik kelas X di SMA Negeri 8 Semarang. Penelitian ini menerapkan pendekatan kuantitatif dan menggunakan metodelogi studi deskriptif. Adapun jumlah sampel penelitian ini yakni 260 siswa kelas X dengan teknik penghimpunan sampel menerapkan sampel jenuh. Perolehan penelitian memperlihatkan penyesuaian diri siswa di SMA Negeri 8 Semarang tahun ajaran 2023/2024 rata-rata berada pada kategori sedang dengan perolehan 40,38%, terdapat siswa dengan perolehan kategori sangat tinggi 1,92%, tinggi 38,07%, dan rendah 19,61 %.